Arugula Sciences

Executive Summary

Arugula Sciences is a San Diego-based clinical-stage biotechnology company developing advanced therapeutics from human perinatal tissues and cells. Its lead asset, an injectable umbilical cord allograft, is currently in Phase 1 trials for osteoarthritis, addressing a large and growing market. The company also has a preclinical pipeline of mesenchymal stem cell and acellular therapies targeting chronic inflammatory and degenerative diseases. With a focus on unmet medical needs, Arugula leverages the unique immunomodulatory and regenerative properties of perinatal tissues to potentially offer safer and more effective alternatives to conventional treatments. The company's approach differentiates it in the competitive cell therapy space, though it remains early-stage with limited public data. Successful proof-of-concept in ongoing trials could unlock significant value and partnership opportunities.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 osteoarthritis trial interim data readout40% success
• Q1 2027IND filing for lead mesenchymal stem cell therapy candidate50% success
• Q4 2026Strategic partnership or licensing deal for acellular therapy platform25% success